Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Celiprolol→

Celiprolol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
56980-93-9
Molecular formula
C20H33N3O4
Molecular weight
379.49 g/mol
Drug class
Selective beta-1 adrenergic receptor antagonist with partial beta-2 agonist activityantihypertensive
Mechanism of action
Blocks cardiac beta-1 adrenergic receptors while exhibiting partial beta-2 agonist activity, reducing heart rate and myocardial workload and producing peripheral vasodilatory effects.
Indications / reported uses
  • Treatment of hypertension and selected angina symptoms in countries where celiprolol is authorised
  • Used in some jurisdictions for vascular Ehlers-Danlos syndrome (vEDS) under specialist protocols; this is not a universal product-approved indication

Sources: NLM MeSH — Celiprolol · PubMed — Celiprolol pharmacology and vascular Ehlers-Danlos syndrome · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Celiprolol Environmental Risk Assessment (ERA) (the Celiprolol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.